Topical Hydromorphone for Wound Healing
Information source: University of Minnesota
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Wound Healing
Intervention: hydromorphone (Drug)
Phase: Phase 1/Phase 2
Status: Terminated
Sponsored by: Hordinsky, Maria K., MD Official(s) and/or principal investigator(s):
Maria Hordinsky, MD, Principal Investigator, Affiliation: University of Minnesota
Robert Hebbel, MD, Principal Investigator, Affiliation: University of Minnesota
Summary
The hypothesis is that topical opioids will hasten wound healing in humans.
Clinical Details
Official title: Topical Hydromorphone for Wound Healing
Study design: Treatment, Randomized, Single Blind, Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Healing rates and microvessel density will be compared statistically for the control-ointment versus hydromorphone-ointment subjects.
Detailed description:
This is based on our published data that morphine is a powerful stimulant of angiogenesis and
our preclinical study of wounds in rats which demonstrate that topical opioids (morphine,
hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on
hydromorphone which was more powerful than morphine as a wound-healer in the rat study.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Self-identified as normal, healthy volunteers age 18-65.
Exclusion Criteria:
- Known bleeding disorder.
Locations and Contacts
Additional Information
Starting date: October 2003
Ending date: May 2007
Last updated: February 6, 2008
|
